Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New chemo cocktail aims to boost survival in kids with rare lymphoma

NCT ID NCT02845882

First seen Mar 18, 2026 · Last updated Jun 22, 2026 · Updated 16 times

Summary

This phase 3 trial tests a modified chemotherapy regimen for 150 Chinese children and teens newly diagnosed with lymphoblastic lymphoma. The goal is to improve event-free survival compared to earlier results. Participants receive a combination of drugs including prednisone, vincristine, and others over several phases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Shanghai Children's Medical Center

    Shanghai, 200127, China

  • West China Second University Hospital

    Chengdu, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

combination chemotherapy (prednisone, vincristine, pegylated-asparaginase, cytarabine, cyclophosphamide, daunorubicin, 6-mercaptopurine, methotrexate)

What this could lead to

If successful, this modified chemotherapy regimen could improve survival rates for children with lymphoblastic lymphoma in China.

What could go wrong

This is a single-country study with 150 participants, so results may not apply broadly. Chemotherapy has significant side effects, and the trial is not testing a cure—ongoing management is still needed.

Conditions

The condition(s) this trial relates to.

lymphoblastic lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.